W

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Business Management
Share
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

South Korea urges exchanges to boost cold storage after Binance hack

South Korean crypto exchanges are already required to hold at least 80% of customer crypto in cold wallets, but the regulator is urging more.…

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

A deceleration in U.S. commercial contract growth gave some Wall Street analysts pause despite Palantir’s earnings beat. Source：MarketWatch

Apple’s iPhone business is booming. Here’s why the stock is falling anyway.

Although iPhone demand remains strong, Apple faces a worsening memory crunch and a slowing services business. Source：MarketWatch

Nasdaq-100 tumbles into its third correction this year as AI worries mount

The “tech wreck” from October continues. Is a bear market next? Source：MarketWatch

Source：https://www.marketwatch.com/story/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can-europe-compete-in-the-high-stakes-global-economy-0a2bcfd0